Detecting the Tumor Prognostic Factors From the YTH Domain Family Through Integrative Pan-Cancer Analysis

Overview

Journal Cancer Inform

Publisher Sage Publications

Specialty Biomedical Engineering

Date 2024 Nov 18

PMID 39553336

Authors

Chong-Ying Zhu

Qi-Wei Yang

Xin-Yue Mu

Yan-Yu Zhai

Wen-Yan Zhao

Zuo-Jing Yin

Affiliations

Soon will be listed here.

Abstract

Objectives: Emerging evidence suggests that N6-methyladenosine (mA) methylation plays a critical role in cancers through various mechanisms. This work aims to reveal the essential role of mA methylation "readers" in regulation of cancer prognosis at the pan-cancer level.

Methods: Herein, we focused on one special protein family of the "readers" of mA methylation, YT521-B homology (YTH) domain family genes, which were observed to be frequently dysregulated in tumor tissues and closely associated with cancer prognosis. Then, a comprehensive analysis of modulation in cancer prognosis was conducted by integrating RNA sequencing (RNAseq) datasets of YTH family genes and clinical information at the pan-cancer level.

Results: YTH family genes were significantly differentially expressed in most of the cancers, particularly increased in Gastrointestinal cancers, and decreased in Endocrine and Urologic cancers. In addition, they were observed to be associated with overall survival (OS) and disease-specific survival (DSS) with various extent, especially in lower grade glioma (LGG), thyroid cancer (THCA), liver hepatocellular carcinoma (LIHC) and kidney clear cell carcinoma (KIRC), so were some "writers" (METLL3, METLL14, WTAP) and "erasers" (FTO, ALKBH5). Further survival analysis illustrated that YTH family genes specifically YTHScore constructed by combining 5 YTH family genes, as well as RWEScore calculated by combining genes from "readers"-"writers"-"erasers" could dramatically distinguish tumor prognosis in 4 representative cancers. As expected, YTHScore presented an equally comparable prognostic classification with RWEScore. Finally, analysis of immune signatures and clinical characteristics implied that, the activity of the innate immune, diagnostic age, clinical stage, Tumor-Node-Metastasis (TNM) stage and immune types, might play specific roles in modulating tumor prognosis.

Conclusions: The study demonstrated that YTH family genes had the potential to predict tumor prognosis, in which the YTHScore illustrated equal ability to predict tumor prognosis compared to RWEScore, thus providing insights into prognostic biomarkers and therapeutic targets at the pan-cancer level.

References

Wang G, Wang H, Ji X, Wang T, Zhang Y, Jiang W . Intratumoral microbiome is associated with gastric cancer prognosis and therapy efficacy. Gut Microbes. 2024; 16(1):2369336. PMC: 11216101. DOI: 10.1080/19490976.2024.2369336. View

Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R . YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 2018; 442:252-261. DOI: 10.1016/j.canlet.2018.11.006. View

Patel A, Yanai I . A developmental constraint model of cancer cell states and tumor heterogeneity. Cell. 2024; 187(12):2907-2918. PMC: 11256907. DOI: 10.1016/j.cell.2024.04.032. View

Lan Q, Liu P, Bell J, Wang J, Huttelmaier S, Zhang X . The Emerging Roles of RNA mA Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance. Cancer Res. 2021; 81(13):3431-3440. DOI: 10.1158/0008-5472.CAN-20-4107. View

Dai X, Shi L, Li Z, Yang H, Wei J, Ding Q . Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers. Front Oncol. 2021; 11:635329. PMC: 8076607. DOI: 10.3389/fonc.2021.635329. View

Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J . RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. Cancer Lett. 2016; 376(1):34-42. DOI: 10.1016/j.canlet.2016.02.022. View

Yuan W, Chen S, Li B, Han X, Meng B, Zou Y . The N6-methyladenosine reader protein YTHDC2 promotes gastric cancer progression via enhancing YAP mRNA translation. Transl Oncol. 2021; 16:101308. PMC: 8681016. DOI: 10.1016/j.tranon.2021.101308. View

Zhang C, Huang S, Zhuang H, Ruan S, Zhou Z, Huang K . YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation. Oncogene. 2020; 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. View

Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

10.

Zhao H, Xu Y, Xie Y, Zhang L, Gao M, Li S . m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer. Front Cell Dev Biol. 2021; 9:650023. PMC: 7970005. DOI: 10.3389/fcell.2021.650023. View

11.

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J . mA demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020; 19(1):40. PMC: 7045432. DOI: 10.1186/s12943-020-01161-1. View

12.

Passaro A, Al Bakir M, Hamilton E, Diehn M, Andre F, Roy-Chowdhuri S . Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell. 2024; 187(7):1617-1635. PMC: 7616034. DOI: 10.1016/j.cell.2024.02.041. View

13.

Liao J, Wei Y, Liang J, Wen J, Chen X, Zhang B . Insight into the structure, physiological function, and role in cancer of m6A readers-YTH domain-containing proteins. Cell Death Discov. 2022; 8(1):137. PMC: 8964710. DOI: 10.1038/s41420-022-00947-0. View

14.

Dong D, Wei J, Wang W, Zhou H, Hong L, Ji G . YTHDC1 promotes the malignant progression of gastric cancer by promoting ROD1 translocation to the nucleus. Cell Biol Toxicol. 2024; 40(1):19. PMC: 10995098. DOI: 10.1007/s10565-024-09859-4. View

15.

Li L, Tang C, Ye J, Xu D, Chu C, Wang L . Bioinformatic analysis of m6A "reader" YTH family in pan-cancer as a clinical prognosis biomarker. Sci Rep. 2023; 13(1):17350. PMC: 10575994. DOI: 10.1038/s41598-023-44143-1. View

16.

Xu F, Li L, Jiang L, Zhang J . Identification of key genes and immune infiltration in multiple myeloma by bioinformatics analysis. Hematology. 2023; 28(1):2264517. DOI: 10.1080/16078454.2023.2264517. View

17.

Luan J, Zhang D, Liu B, Yang A, Lv K, Hu P . Immune-related lncRNAs signature and radiomics signature predict the prognosis and immune microenvironment of glioblastoma multiforme. J Transl Med. 2024; 22(1):107. PMC: 10821572. DOI: 10.1186/s12967-023-04823-y. View

18.

Fang Z, Mei W, Qu C, Lu J, Shang L, Cao F . Role of m6A writers, erasers and readers in cancer. Exp Hematol Oncol. 2022; 11(1):45. PMC: 9361621. DOI: 10.1186/s40164-022-00298-7. View

19.

Han D, Zhou T, Li L, Ma Y, Chen S, Yang C . AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease. Circulation. 2024; 149(20):1578-1597. DOI: 10.1161/CIRCULATIONAHA.123.065213. View

20.

Liu S, Lin C, Lin X, Lin P, He R, Pan X . NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression. Cancer Res. 2024; 84(19):3207-3222. DOI: 10.1158/0008-5472.CAN-23-4062. View